NovoHelix is constantly evaluating new DNA-writing and DNA-editing technologies to advance our genome engineering platform including the ability to multiplex with novel programmable endonucleases for custom model generation. Leveraging our expertise for generating targeted mutations in animal or cellular models, we routinely create constitutive knockouts, conditional knockouts (cKO), knock-ins, deploy site-specific recombinases for conditional genetic circuits and design gene drives for super-Mendelian inheritance. NovoHelix has a customizable pipeline for targeted modification of any genomic locus.
In spite of the epigenetic barriers that impede reprogramming (Matoba & Zhang 2018), animal cloning by SCNT has become the established gold-standard biotechnology for the production of large animal models including cows, goats, pigs and sheep (Estrada et al 2008). Precision genome engineering with the CRISPR-Cas technological platform accelerates the potential for seamless modifications by gene knockout and knockin. At NovoHelix, we have optimized gene-editing techniques to address the critical need for large animal models across a variety of disciplines in biomedicine and translational research.
Animal models are used virtually in all fields of biomedical research including regenerative medicine, oncology, embryology, functional genomics, biotechnology, and genome engineering. Rapid advancements in genome engineering with programmable nucleases have opened the capability to model in comparative animal species including large animals such as pigs, that may adequately replicate the human condition where traditional rodent models have deficiencies. Our model design team is experienced with multiple DNA-writing and DNA-editing technologies including CRISPR-Cas systems, TALENs, zinc finger nucleases (ZFN), meganucleases, gene targeting by homologous recombination and phage recombineering. We have a reputation for advancing biomedical model generation in both rodents and livestock, and these animal models continue to play critical roles in translational research and the advancement of human health. Please explore our animal modeling services below and contact us through our general inquiry or quote requests to address specific end-user application needs.
NovoHelix combines innovative tools and services with deep practical expertise for custom cell model engineering for biomedical and translational research and synthetic biology. Our CRISPR gene editing services includes stem cell technologies for targeting in human and mouse pluripotent stem cells including embryonic stem (ES) cell lines, induced pluripotent stem (iPS) cells and embryonic germ (EG) cells. Our dedicated team of scientists are familiar with classical gene targeting by the process of homologous recombination as pioneered by Nobel laureates Oliver Smithies and Mario Capecchi. Moreover, NovoHelix entered into the genome engineering space prior to the CRISPR era with practical expertise testing artificial designer nucleases like the polydactyl zinc finger nucleases (ZFNs) built through context-dependent assembly, and transcription activator-like effector nucleases (TALENs). Our optimized CRISPR workflows and experience have not only improved low editing efficiencies but also allowed our clients to increase the scope of possible edit types like large cassette knockins or the number of simultaneous genome modifications such as biallelic targeting with different reporter gene cassettes and editing of multiple genetic loci. Whether it’s a single gene edit needed to create an isogenic normal human and diseased cell model or a library of mutagenized cells to scan all possible amino acid substitutions within a region of a protein, NovoHelix has a customizable pipeline to meet your timeline and budget.
The ability to manipulate genes and genomes in a systematic way using DNA sequence-specific technologies such as lambda red recombineering and CRISPR-based gene editing enables faster generation of industrial microbial strains. New designer microbes function as modern day workhorses converting biomass into biologics such monoclonal antibodies, or natural products, biofuels, food additives and recombinant enzymes. At NovoHelix we leverage synthetic evolution tools with combinatorial approaches to rapidly develop highly optimized and productive microbial cell factories. Please explore our microbial services below and contact us through our general inquiry or quote requests to address specific end-user application needs.
NovoHelix has not received any reviews.
NovoHelix has not received any endorsements.